PVLA Share Price Performance
US$142.04
91.91 (183.34%)
38.0% undervalued intrinsic discount
US$229.00
Fair Value
Price US$142.04
AnalystConsensusTarget US$229.00
Fair ValueUS$229.00
Share Pricen/a
Seeking Alpha • Aug 19
Palvella Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
PVLA Community Narratives
AN
Fair Value
·Fair Value US$229 38.0% undervalued intrinsic discount
Rare Disease Pipeline And First Approval Opportunity Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rare Disease Pipeline And First Approval Opportunity Will Drive Long Term Upside Potential
Catalysts About Palvella Therapeutics Palvella Therapeutics develops topical therapies for serious rare skin diseases and vascular malformations with no FDA approved treatment options. What are the underlying business or industry changes driving this perspective?Read more
AN
US$229
38.0% undervalued intrinsic discount
Fair Value
Profit Margin
18.66%
Future PE
134.62x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Rare Disease Pipeline And First Approval Opportunity Will Drive Long Term Upside Potential
Fair Value: US$229 38.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Palvella Therapeutics, Inc. Key Details
About PVLA
- Founded
- n/a
- Employees
- 29
- CEO
- WebsiteView website
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
